Bausch+Lomb announced today that an affiliate acquired Elioses Vision,developer of a minimally invasive glaucoma surgery(MIGS)procedure.
博士倫(lun) 公司今天宣布，其子公司收購了微創青光眼手術（MIGS）開發商Elioses Vision公司。
The Elioses procedure uses an excimer laser to treat glaucoma in conjunction with cataract surgery without implants.Bausch+Lomb believes the deal enhances its glaucoma portfolio which already features pharmaceutical and surgical approaches.
Elioses手術使用準分子激光治療青光眼，同時進行白內(nei) 障手術，無需植入人工晶體(ti) 。博士倫(lun) 認為(wei) ，這項交易增強了其青光眼產(chan) 品組合，該產(chan) 品組合已包括藥物和手術方法。
Compared to other glaucoma surgery techniques,MIGS offers a safe and effective approach to lowering intraocular pressure.It also features a faster recovery time,according to a news release.Elioses’version offers a tissue-friendly,precision,non-thermal laser-based and highly adoptable procedure for the treatment of glaucoma.The company currently offers the CE-marked technology in Europe and is pursuing FDA approval.
與(yu) 其他青光眼手術技術相比，MIGS是一種安全有效的降低眼壓的方法。據一份新聞稿稱，它還具有恢複時間更短的特點。Elioses公司的版本為(wei) 青光眼治療提供了一種組織友好、精確、基於(yu) 非熱激光且高度可采用的手術方法。該公司目前在歐洲提供獲得CE認證的技術，並正在申請美國食品和藥物管理局的批準。
Former Elioses Chair and CEO Elliot Friedman said the companies aim to make combining cataract and glaucoma treatment the new standard of care.Friedman said the global presence of Bausch+Lomb makes that“even more attainable.”
艾裏奧斯公司前董事長兼首席執行官埃利奧特-弗裏德曼（Elliot Friedman）說，兩(liang) 家公司的目標是使白內(nei) 障和青光眼的聯合治療成為(wei) 新的治療標準。弗裏德曼說，博士倫(lun) 的全球業(ye) 務使這一目標“更容易實現”。
“Today’s announcement further demonstrates our commitment to investing in smart,innovative technologies that enable eye care professionals to better address the evolving needs of their patients,”said Luc Bonnefoy,president,Surgical,Bausch+Lomb.“The ELioses system offers a differentiated approach for the treatment of glaucoma,a condition expected to increase in prevalence by 47%from 2020 to 2040.”
“博士倫(lun) 公司手術部總裁Luc Bonnefoy說："今天的聲明進一步證明了我們(men) 投資於(yu) 智能創新技術的承諾，這些技術使眼科護理專(zhuan) 業(ye) 人員能夠更好地滿足患者不斷變化的需求。“ELioses係統為(wei) 治療青光眼提供了一種與(yu) 眾(zhong) 不同的方法，預計從(cong) 2020年到2040年，青光眼的發病率將增加47%。
